BFLY vs DFTX
Butterfly Network, Inc. vs Definium Therapeutics, Inc. — AI-powered side-by-side comparison
BFLY
Butterfly Network, Inc.
67
Buy
VS
DFTX
Definium Therapeutics, Inc.
62
Buy
| Metric | BFLY | DFTX |
|---|
| AI Score |
67
|
62
|
| Price |
$9.36
|
$40.91
|
| P/E Ratio |
-32.38×
|
-11.89×
|
| ROE |
-39.3%
|
-55.3%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
51.1%
|
0.0%
|
| Debt / Equity |
0.10×
|
0.04×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
66.4
|
36.3
|
| Beta |
2.084
|
2.237
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for BFLY versus DFTX.
BFLY leads by 5 points.
BFLY scores 67/100 (Buy) versus DFTX at 62/100 (Buy).
BFLY Committee View
67% agreement
6 analysts
The primary driver is revenue growing 28.1% yoy -- genuine top-line momentum. The main limiting factor is roe of only -38.4% -- cheap may mean cheap for a reason. The committee is constructive but not yet at full conviction.
Bull Case
- Revenue growing 28.1% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -38.4% -- cheap may mean cheap for a reason — Value
- Bollinger bandwidth of 52.6% signals elevated volatility — Risk
DFTX Committee View
60% agreement
5 analysts
Positive signals support the current rating — low leverage (debt-to-equity 0.12) -- balance sheet can absorb a shock. The committee sees sufficient evidence to maintain the constructive view.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.12) -- balance sheet can absorb a shock — Risk
Bear Case
- Price-to-book of 4.0x prices in significant intangible value — Value
- ROE of only -85.2% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical